[1]邵国强,王自正.整合素αvβ3受体靶向肿瘤显像研究进展[J].国际放射医学核医学杂志,2014,38(1):33-36.[doi:10.3760/cma.j.issn 1673-4114.2014.01.007]
　Shao Guoqiang,Wang Zizheng.Integrin αvβ3 targeted tumor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):33-36.[doi:10.3760/cma.j.issn 1673-4114.2014.01.007]
点击复制

整合素αvβ3受体靶向肿瘤显像研究进展(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
38
期数:
2014年第1期
页码:
33-36
栏目:
出版日期:
2014-01-25

文章信息/Info

Title:
Integrin αvβ3 targeted tumor imaging
作者:
邵国强;  王自正
南京医科大学附属南京医院核医学科, 210006
Author(s):
Shao Guoqiang;  Wang Zizheng
Department of Nuclear Medicine, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China
关键词:
整合素αVβ3; 精氨酸-甘氨酸-天冬氨酸; 肿瘤; 靶向显像; 疗效评价
Keywords:
Integrin αvβ3; Arginine-glycine-aspartic acid; Neoplasms; Targeted imaging; Therapeutic effect evaluation
DOI:
10.3760/cma.j.issn 1673-4114.2014.01.007
摘要:
整合素αvβ3高表达于肿瘤细胞和肿瘤新生血管内皮细胞表面,而在正常组织和成熟血管内皮细胞表面呈低水平表达或不表达,整合素αvβ3能够与体内外含精氨酸-甘氨酸-天冬氨酸(RGD)序列的物质发生特异性结合。通过对RGD肽进行结构修饰、多聚化等来构建体内理化性能稳定的RGD肽和RGD-蛙皮素等融合肽,再通过不同的偶联剂介导完成RGD肽的不同放射性核素(18F、111In、64Cu、68Ga、125I、99Tcm、123I、86Y等)标记,成为近年来肿瘤靶向显像的研究热点,部分临床实验正在国内外进行有效开展。通过PET/CT、SPECT/CT和PET/MRI多模态显像定量检测肿瘤整合素αvβ3受体的表达水平,来完成抗肿瘤新生血管生成治疗患者的筛选、疗效预测和实时监测,已成为近年来研究的焦点和新的发展方向。
Abstract:
Integrin αvβ3, highly expressed in tumor cells and tumor vasculature endothelial cells but rarely expressed in mature vessels or normal tissues, and it can specifically recognize and combine with the peptides which containing tripeptide sequence Arg-Gly-Asp (RGD). Some stable RGD peptides and RGD-bombesin heterodimers are synthesized by structure modification and muhimerization of RGD peptides. These RGD peptides labeled with gamma-emitting and positron-emitting nuclides have been reported as the target tumor imaging research hotspot, and clinical trials are under way. The PET/CT, SPECT/CT and PET/MRI muhimode imaging are focused on the quantitative analysis of tumor integrin αvβ3 expression level and anti-angiogenesis patient screening, therapeutic effect evaluation and real time monitoring.

参考文献/References:

[1] Folkman J. Role of angiogenesis in tumor growth and metastasis[J]. Semin Oncol, 2002, 29(6 Suppl 16):S15-18.
[2] Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using[18F]Galacto-RGD identifies the level of integrin alpha (v) beta3 expression in man[J]. Clin Cancer Res, 2006, 12(13):3942-3949.
[3] Liu Z, Wang F. Development of RGD-Based Radiotracers for Tumor Imaging and Therapy:Translating from Bench to Bedside[J]. Curr Mol Med, 2013, 13(10):1487-1505.
[4] Jiao Y, Feng X, Zhan Y, et al. Matrix metalloproteinase-2 promotes αvβ3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin[J/OL]. PLoS One, 2012, 7(7):e41591[2013-01-15]. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.O041591.
[5] Haubner R, Wester HJ, Reuning U, et al. Radiolabeled αvβ3 integrin antagonists:a new class of tracers for tumor targeting[J]. J Nucl Med, 1999, 40(6):1061-1071.
[6] Monaco A, Zoete V, Alghisi GC, et al. Synthesis and in vitro evalu-ation of a novel radioligand for αvβ3 integrin receptor imaging:[18F]FPPA-c (RGDfK)[J]. Bioorg Med Chem Lett, 2013, 23(22):6068-6072.
[7] Decristoforo C, Hernandez Gonzalez I, Carlsen J, et al. 68Ga-and 111In-labelled DOTARGD peptides for imaging of αvβ3 integrin expression[J]. Eur J Nucl Med Mol Imaging, 2008, 35(8):1507-1515.
[8] Liu Z, Niu G, Shi J, et al. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers:promising agents for tumor integrin alphavbeta3 PET imaging[J]. Eur J Nucl Med Mol Imaging, 2009, 36(6):947-957.
[9] Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacro-cyclic complexes[J]. J Med Chem, 2004, 47(6):1465-1474.
[10] Zhou Y, Kim YS, Chakraborty S, et al. 99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin αvβ3 expression[J]. Mol Imaiging, 2011, 10(5):386-397.
[11] Wang L, Shi J, Kim YS, et al. Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers[J]. Mol Pharm, 2009, 6(1):231-245.
[12] Selvaraj R, Liu S, Hassink M, et al. Tetrazine-trans-cyclooctene ligation for the rapid construction of integrin αvβ3 targeted PET tracer based on a cyclic RGD peptide[J]. Bioorg Med Chem Lett, 2011, 21(17):5011-5014.
[13] 靳存敬,史继云,刘妍,等.99Tcm标记的PEG4/2PEG4修饰的环状RGD二聚体体内外性质的对比[J].核化学与放射化学,2010,32(5):287-292.
[14] Ma Q, Ji B, Jia B, et al. Differential diagnosis of solitary pulmonary nodules using 99mTc-3P4-RGD2 scintigraphy[J]. Eur J Nucl Med Mol Imaging, 2011, 38(12):2145-2152.
[15] Dijkgraaf I, Yim CB, Franssen GM, et al. PET imaging of αvβ3 integrin expression in tumours with 68Ga-labelled mono-, di-and tetrameric RGD peptides[J]. Eur J Nucl Med Mol Imaging, 2011, 38(1):128-137.
[16] Lee HY, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles[J]. J Nucl Med, 2008, 49(8):1371-1379.
[17] Jackson AB, Nanda PK, Rold TL, et al. 64Cu-NO2A-RGD-GIu-6-Ahx-BBN(7-14)NH2:a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer[J]. Nucl Med Biol, 2012, 39(3):377-387.
[18] Haubner R, Beer A J, Wang H, et al. Positron emission tomography tracers for imaging angiogenesis[J]. Eur J nucl Med Mol Imaging, 2010, 37 suppl 1:S86-103.

相似文献/References:

[1]黄建敏,解朋,刘晓梅,等.以整合素αvβ3为靶点的肿瘤分子显像及靶向治疗[J].国际放射医学核医学杂志,2015,39(3):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
　Huang Jianmin,Xie Peng,Liu Xiaomei,et al.Integrins αvβ3 in molecular imaging and targeted therapy of neoplasms[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):256.[doi:10.3760/cma.j.issn.1673-4114.2015.03.015]
[2]郝玉美,贺欣,宋娜玲.靶向肿瘤新生血管整合素αvβ3受体显像研究现状及进展[J].国际放射医学核医学杂志,2014,38(3):179.[doi:10.3760/cma.j.issn.1673-4114.2014.03.010]
　Hao Yumei,He Xin,Song Naling.Progress on tumor angiogenesis imaging targeting integrin αvβ3 receptor[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):179.[doi:10.3760/cma.j.issn.1673-4114.2014.03.010]
[3]陈素芸.放射性核素标记RGD多肽在整合素受体显像中的应用[J].国际放射医学核医学杂志,2007,31(3):129.
　CHEN Su-yun.Application of radiolabeled RGD peptides in imaging of integrin receptor[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(1):129.
[4]赵龙,罗作明,孙龙,等.新型αvβ3和Neuropilin-1双靶点正电子成像探针18F-FAl-NOTA-RGD-ATWLPPR用于脑胶质瘤的PET显像研究[J].国际放射医学核医学杂志,2017,41(4):233.[doi:10.3760/cma.j.issn.1673-4114.2017.04.001]
　Zhao Long,Luo Zuoming,Sun Long,et al.Imaging of glioma with an integrin αvβ3 and neuropilin-1 dual-targeted PET probe 18F-FAl-NOTA-RGD-ATWLPPR[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(1):233.[doi:10.3760/cma.j.issn.1673-4114.2017.04.001]
[5]刘晓梅,魏玲格,张芳.以血管生成为分子靶点的放射性核素显像分子探针在肿瘤个体化用药中的应用[J].国际放射医学核医学杂志,2017,41(5):363.[doi:10.3760/cma.j.issn.1673-4114.2017.05.011]
　Liu Xiaomei,Wei Lingge,Zhang Fang.Targeting angiogenesis of radionuclide imaging molecular probes for tumor individualized medicine[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(1):363.[doi:10.3760/cma.j.issn.1673-4114.2017.05.011]

备注/Memo

备注/Memo:
收稿日期:2013-01-15。
基金项目:国家自然科学基金(81071185);江苏省自然基金(SBK20134281)
通讯作者:王自正(Email:guoqiangshao@163.com)
更新日期/Last Update: 1900-01-01